FORCE’s eXamining the Relevance of Articles for Young Survivors (XRAYS) program is a reliable resource for breast cancer research-related news and information. XRAYS reviews new breast cancer research, provides plain-language summaries, and rates how the media covered the topic. XRAYS is funded by the CDC.
The American Society of Breast Surgeons published a consensus statement about genetic testing for hereditary breast cancer on February 10, 2019. It includes five recommendations about the genetic testing process and who should be tested. Among these is the recommendation that all breast cancer patients get genetic testing, as well as women who do not have breast cancer but fit the National Comprehensive Cancer Network (NCCN) guidelines. (3/25/19)
A study showed that African American women experienced greater burdens in obtaining information at each step compared to white women. Racial differences in preventive choices correlated with differences in information and provider access. (3/14/19)
Does having children alter the risk of breast cancer? Women who give birth have a lower lifetime risk of breast cancer. However, newer data suggests that breast cancer risk increases immediately after childbirth. This XRAYS reviews a meta-analysis from Hazel Nichols, PhD and colleagues published in December 2018 that examines data from the Premenopausal Breast Cancer Collective Group seeking to clarify this issue. (12/28/18)
A study in JAMA Surgery this year examined the factors that impact genetic testing after a breast cancer diagnosis. This study suggests that the attitudes of attending surgeons about genetic testing have the most impact on whether patients receive testing. (10/6/18)
Women with inherited mutations in genes that increase breast and ovarian cancer risk have an additional challenge: coping with how those mutations impact their families and how a family member’s cancer experience can shape their own perception. In a recent U.S. News and World Report article, Elaine Howley explores how a woman's decisions about healthcare, cancer prevention and treatment are affected by experience with cancer in the family. (9/25/18)
Does hormone therapy (HT) alter the risk of breast cancer for woman carrying a BRCA1 mutation who have never been diagnosed with cancer? In this JAMA Oncology study, researchers showed that among women with
BRCA1 mutations, HT use did not increase breast cancer rates for 10 years after ovary removal. More women taking combined estrogen plus progesterone developed breast cancer compared to those taking estrogen only, though this difference was not statistically significant. (9/7/18)
Current breast cancer treatments can negatively affect cardiovascular health. Recently, the American Heart Association released its first scientific statement on cardiovascular disease and breast cancer. This statement includes a comprehensive overview of the prevalence of both diseases, shared risk factors, cardiotoxic effects of therapy and the prevention and treatment of cardiovascular disease in breast cancer patients. (5/2/18)
When a woman is newly diagnosed with a BRCA mutation, she faces many risk management decisions. Although many of these decisions impact family planning, little guidance is available on how to communicate this information. This study examines female previvors’ advice on effective strategies for discussing family planning decisions. (03/28/18)
The risk of breast cancer is exceptionally high in women who have a personal or family history of breast cancer or who carry a mutation in BRCA or certain other genes. More frequent screening is one strategy for early detection of breast cancer for these women. Study results presented at the 2017 San Antonio Breast Cancer Symposium suggest that MRI screening every 6 months may be more effective than the currently recommended annual breast
MRI and annual mammogram in detecting early stage breast cancers-which are more treatable-in high-risk women. (2/1/18)
Nipple-sparing mastectomy (NSM) offers better cosmetic results for women who have immediate breast reconstruction (at the same time as their mastectomy). Over the past decade, NSM has gained popularity among surgeons and patients. Studies show that women who keep their own nipples have higher rates of satisfaction and psychological well-being after mastectomy and reconstruction compared to women who lose their nipples. However, little data exists on the long-term risk of recurrence following NSM. New research adds to a growing body of evidence suggesting that risk of recurrence is low after NSM in carefully selected patients with breast cancer. (1/25/18)
Hormonal therapy significantly reduces the risk of recurrence for women with early-stage estrogen receptor-positive breast cancer. Standard hormonal therapy is given for 5 years; extending that therapy for a longer period offers additional protection but has added side effects. A new study looked at women who stopped hormonal therapy after 5 years and identified factors that may guide the decision to extend treatment. (12/21/17)
On December 7, 2017 the New England Journal of Medicine published results from a study by Lina Mørrch of the University of Copenhagen and colleagues showing that hormonal contraceptives (birth control) increase the risk of breast cancer. The study is unique because it is one of the first to specifically assess the breast cancer risk associated with newer, low-dosage methods of contraception. The large and significant effort analyzed medical data of nearly 1.8 million young women in Denmark on average for over 10.9 years. Results were covered widely in the U.S. by many major media outlets, including the New York Times, USA Today, Forbes and Time. (12/14/17)
Korin Miller’s piece for SELF magazine focuses on why women with dense breasts may need more than a screening mammogram. Miller highlights the recent story in People magazine of Jill Goodacre, a former Victoria’s Secret model and the wife of recording artist and talk show host Harry Connick Jr. Goodacre told of her breast cancer diagnosis 5 years ago after having additional screening of her dense breast tissue following a normal
The link between alcohol intake and breast cancer is well known, but most studies have involved only White women. Recently, a large study of more than 22,000 African American (AA) women found that similar to White women, increased alcohol consumption is associated with a greater risk of breast cancer. (10/27/17)
National guidelines recommend that patients meet with a genetics expert before undergoing genetic testing for cancer risk. Genetic counseling can help patients decide whether genetic testing is right for them and order the most appropriate test. Once test results are available, genetics experts also help patients understand their results. Over the last decade, the popularity of direct-to-consumer (DTC) genetic testing, such as 23andMe has grown. Some genetic tests are marketed to consumers on television, in print advertisements, and on the Internet. These “at-home” genetic tests give people direct access to their genetic information without first involving a healthcare provider in the process. A recent report outlines the benefits and limitations of DTC genetic testing. (10/20/17)
Angelina Jolie published an editorial in the New York Times in 2013 about her choice to have a double mastectomy after finding out she was positive for a BRCA1 mutation. Researchers from a recent study claim that her celebrity endorsement of BRCA testing may have missed its target audience (previvors), due to the increase in BRCA testing following publication of the editorial but a decrease in the number of mastectomies performed. However, the study failed to take into account that many women without breast cancer do not pursue mastectomy in the months following genetic testing. (1/4/17)
Today, more women know they can have breast reconstruction after removing their breasts for cancer treatment or risk reduction. But what about choosing not to undergo reconstruction? Roni Caryn Rabin writes about the experiences of women who decide against reconstruction in her New York Times piece “‘Going Flat’ After Breast Cancer.” (12/14/16)
What are reasons to get or not get genetic testing? Cynthia Graber gives her thoughts on the matter in her Wired opinion piece, "Why I Won't Get the Genetic Test for Breast Cancer." (11/15/16)
Cigarette smoking is an important public health issue that causes more than 480,000 deaths annually. Smoking increases the risk of many diseases, from heart disease to stroke. This research indicates that smoking before and or after a diagnosis of breast cancer affects survival, and also shows that it is never too late to quit smoking.
Many treatments that lower estrogen levels also reduce breast cancer risk. Unfortunately, these treatments are also associated with negative side effects. A recent study looked at the effect of regular aerobic exercise on the estrogen levels of women who are at high risk for breast cancer.
Multigene panel testing can look for mutations in many genes associated with increased cancer risk. Some panels include genes associated with increased risk of multiple cancers, including breast, ovarian, colon, and gastric cancers. This study demonstrates that multigene panel tests yield findings that can change the care for patients by uncovering cancers for which they are at increased risk. (9/15/15)